Prednisolone Acetate

Summary

Prednisolone Acetate (CHEMBL1152) is an approved small molecule; indicated across 16 conditions including atopic conjunctivitis and anemia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 16 conditions
• Clinical trials: 37
• Chemistry: 402.5 Da · C23H30O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1152
Name	Prednisolone Acetate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5834
Molecular formula	C23H30O6
Molecular weight	402.5
InChIKey	LRJOMUJRLNCICJ-JZYPGELDSA-N

SMILES: CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)O

IUPAC name: [2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate

Also known as: Econopred, Flo-pred, Meticortelone, NSC-10966, Omnipred, Pred forte, Pred fte, Pred mild, Prednisolone acetate, Prednisolone acetate component of pred-g, Prednisoloni acetas, Sterane

Patent coverage: 3,756 distinct patent families (12,111 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Progesterone receptor, Hypoxia-inducible factor 1-alpha.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HIF1A	7.6	Potency	25.1	nM	CHEMBL_ACT_4130811
HIF1A	7.6	Potency	25.1	nM	CHEMBL_ACT_4519088

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

16 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
atopic conjunctivitis	4	MONDO:0005642	EFO:0007141
anemia	4	MONDO:0002280	MONDO:0002280
multiple sclerosis	4	MONDO:0005301	MONDO:0005301
sciatica	3	MONDO:0024333	HP:0011868
anterior uveitis	3	MONDO:0006651	EFO:1000811
uveitis	3	MONDO:0020283	EFO:1001231
eye infectious disorder	3	MONDO:0043885	EFO:1001888
cataract	3	MONDO:0005129	MONDO:0005129
carpal tunnel syndrome	3	MONDO:0007275	EFO:0004143
iritis	2	MONDO:0006814	EFO:1000997
retinal vein occlusion	2	MONDO:0006951	EFO:1001157
keratoconus	1	MONDO:0015486	MONDO:0015486

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 37.

Phase distribution

Phase	Trials
PHASE4	18
Not specified	7
PHASE3	6
PHASE2	4
PHASE2/PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00134992	PHASE4	COMPLETED	A Study to Compare Ocular Safety and Tolerability of Prednisolone Acetate 0.5% Eye Drops Versus Vehicle in Healthy Volunteers
NCT00170729	PHASE4	COMPLETED	A Study to Compare Ocular Safety and Tolerability of Eye Drops Containing Prednisolone Acetate in Patients With Intraocular Inflammation After Cataract Surgery
NCT00345046	PHASE4	COMPLETED	A Comparison of Three Different Formulations of Prednisolone Acetate 1%
NCT00348244	PHASE4	COMPLETED	Ketorolac vs. Steroid in the Prevention of CME
NCT00407017	PHASE4	COMPLETED	Therapeutic Variables in Cataract Surgery
NCT00433225	PHASE4	COMPLETED	Efficacy of Topical Ketorolac Versus Placebo for Improving Visual Outcomes Following Multifocal IOL Implantation
NCT00698724	PHASE4	COMPLETED	Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care
NCT00758199	PHASE4	COMPLETED	Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery
NCT01193504	PHASE4	UNKNOWN	Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification
NCT01939691	PHASE4	TERMINATED	Macular Edema Nepafenac vs. Difluprednate Uveitis Trial
NCT04168112	PHASE4	COMPLETED	Intracanalicular Dexamethasone Insert for Post-Corneal Cross-Linking Inflammation and Pain- The LINK Study
NCT04273282	PHASE4	COMPLETED	A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%
NCT04351737	PHASE4	COMPLETED	Dextenza for Post-operative Treatment of Pterygium
NCT04464629	PHASE4	TERMINATED	Assessing the Efficacy and Safety of DEXTENZA in Pseudo Phakic Patients Undergoing Gas Bubble Repair and Laser Following Retinal Detachment
NCT04563299	PHASE4	TERMINATED	Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections
NCT04863742	PHASE4	UNKNOWN	Evaluation Of Vision Recovery And Comfort Index In Patients With Borderline/Mild Dry Eyes Undergoing FLACS With Premium IOL
NCT05023304	PHASE4	COMPLETED	In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery
NCT05768204	PHASE4	UNKNOWN	Research on the Treatment of Severe Community-acquired Pneumonia in Children
NCT00493064	PHASE2/PHASE3	COMPLETED	To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions
NCT00501579	PHASE3	COMPLETED	Study of Difluprednate in the Treatment of Uveitis
NCT00854061	PHASE3	COMPLETED	Study of T-PRED(TM) Compared to Pred Forte(R) II
NCT01482897	PHASE3	TERMINATED	Efficacy of corticoïd Infiltration Via Sacro-coccygien Hiatus in Discal Sciatica
NCT01853072	PHASE3	COMPLETED	Nepafenac Once Daily for Macular Edema - Study 1
NCT01872611	PHASE3	COMPLETED	Nepafenac Once Daily for Macular Edema - Study 2
NCT03596723	PHASE3	TERMINATED	KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children
NCT00699803	PHASE2	COMPLETED	Study of T-PRED(TM) Compared to Pred Forte(R)
NCT01448213	PHASE2	COMPLETED	Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)
NCT05461261	PHASE2	UNKNOWN	The Efficacy and Safety of Docetaxel Combined With Platinum for Metastatic Hormone-sensitive Prostate Cancer
NCT06679153	PHASE2	COMPLETED	A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis
NCT05620901	EARLY_PHASE1	COMPLETED	DEXTENZA in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia
NCT03415828	Not specified	RECRUITING	Ethanol Gel Versus Steroid in Refractory Lumbar Discogenic Pain
NCT00478036	Not specified	TERMINATED	Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells
NCT01024322	Not specified	TERMINATED	Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
NCT01189864	Not specified	TERMINATED	Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
NCT02412059	Not specified	COMPLETED	Topical Use of Corticosteroid to Prevent Epiretinal Membrane Following Retinal Tear
NCT02416128	Not specified	WITHDRAWN	Use of Topical Euphrasia, a Homeopathic Remedy in Ophthalmology
NCT05248139	Not specified	UNKNOWN	Safety and Effectiveness of Drop-free Small Incision Cataract Surgery

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).